| Title: |
Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder |
| Authors: |
Jun, JS; Kim, R; Byun, JI; Kim, TJ; Lim, JA; Sunwoo, JS; Lee, ST; Jung, KH; Park, KI; Chu, K; Kim, M; Lee, SK; Jung, KY |
| Contributors: |
112418; 김, 태준 |
| Publisher Information: |
John Wiley and Sons Inc. |
| Publication Year: |
2019 |
| Subject Terms: |
Adult; Double-Blind Method; Female; Hong Kong; Humans; Male; Melatonin / administration & dosage; Melatonin / therapeutic use; Middle Aged; Pilot Projects; Polysomnography / methods; REM Sleep Behavior Disorder / complications; REM Sleep Behavior Disorder / drug therapy; Sleep / drug effects; Surveys and Questionnaires; Treatment Outcome; psy; envir |
| Description: |
OBJECTIVE: We investigated the effects of prolonged-release melatonin (PRM) on idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD). METHODS: In this 4-week, randomized, double-blind, placebo-controlled pilot study, 30 participants with polysomnography-confirmed iRBD were assigned to receive PRM 2 mg per day, PRM 6 mg per day, or placebo. Medication was administered orally 30 min before bedtime. Primary outcomes included scores from the Clinical Global Impression-Improvement (CGI-I) and the Korean version of the RBD questionnaire-Hong Kong (RBDQ-KR). The secondary outcomes included RBDQ-KR factor 1 and factor 2 subscores, the Pittsburgh Sleep Quality Index score, the Epworth Sleepiness Scale score, the Short Form Health Survey version 2 score, and the frequency of dream-enacting behaviors assessed using a sleep diary. RESULTS: After 4 weeks, there were no differences in the proportions of patients with a CGI-I score of much improved or very much improved among the study groups. In addition, RBDQ-KR scores and secondary outcomes were not improved in all groups at 4 weeks, and there were no differences between the groups. CONCLUSION: Our findings suggest that PRM may not be effective in treating RBD-related symptoms within the dose range used in this study. Further studies using doses higher than 6 mg per day are warranted. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
http://repository.ajou.ac.kr/handle/201003/18938 |
| Availability: |
http://repository.ajou.ac.kr/handle/201003/18938 |
| Rights: |
undefined |
| Accession Number: |
edsbas.F13B4F27 |
| Database: |
BASE |